IQVIA Holdings has recently seen its consensus analyst price target rise significantly, climbing from $223.42 to $246.84.

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announced the launch of the Patient Centered Endpoints (PCE) solution, an innovative science and ...

On November 5, 2025, IQVIA Holdings Inc. announced the appointment of Dr. William G. Kaelin Jr. to its Board of Directors. Dr. Kaelin, a Nobel Prize-winning scientist with extensive expertise in ...

Nov 1 (Reuters) - IQVIA Holdings (IQV.N), opens new tab cut its full-year profit forecast on Wednesday, citing weakness in demand for its analytics and medical technology solutions along with the ...

IQVIA Holdings Inc. IQV yesterday unveiled a clinical trial technology platform, One Home for Sites. The platform streamlines the process of management of trials by acting as a single sign-on and a ...

New multiyear collaboration between Florence Healthcare and IQVIA to ensure research sites participating in IQVIA studies have access to best-in-class site enablement technology to streamline ...

IQVIA's third quarter results reflected stable operational execution, with revenue and profit slightly ahead of Wall Street ...

Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA) 4.9x Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA) 4.5x ...

IQVIA is trading at 18.2x, which is a discount compared to the industry average of 35.2x. IQV has better operating margins, operational efficiency, strong cash flows, and moderate leverage. The life ...